secwatch / observer
8-K filed February 17, 2023, 6:59 PM ET ticker PAVM CIK 0001624326
other material confidence high sentiment positive materiality 0.65

PAVmed subsidiary terminates MSA with ResearchDx, saves $2.725M; settles EF Hutton lawsuit for $450k

PAVmed Inc.

item 1.02item 8.01item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PAVmed Inc. terminated Management Services Agreement with ResearchDx, Inc. valued at Termination reduces earnout and management fees from $3,450,000 to $725,000, resulting in net saving (effective 2023-02-10).

Action
termination
Counterparty
ResearchDx, Inc.
Value
Termination reduces earnout and management fees from $3,450,000 to $725,000, resulting in net saving
Effective
2023-02-10
Exact text from the filing
On February 14, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), and LucidDx Labs Inc. (“LucidDx Labs”), a wholly owned subsidiary of Lucid Diagnostics, entered into an agreement (the “ Termination Agreement ”) with ResearchDx, Inc. (“ RDx ”), pursuant to which the parties mutually agreed to terminate the Management Services Agreement, dated as of February 25, 2022, by and between LucidDx Labs and RDx (the “ MSA ”), without cause. The termination was effective as February 10, 2023.
View on SEC.gov

Browse all material agreements →

PAVmed Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-005455
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.